Jean-Philippe ThiranJean-Philippe Thiran was born in Namur, Belgium, in August 1970. He received the Electrical Engineering degree and the PhD degree from the Université catholique de Louvain (UCL), Louvain-la-Neuve, Belgium, in 1993 and 1997, respectively. From 1993 to 1997, he was the co-ordinator of the medical image analysis group of the Communications and Remote Sensing Laboratory at UCL, mainly working on medical image analysis. Dr Jean-Philippe Thiran joined the Signal Processing Institute (ITS) of the Swiss Federal Institute of Technology (EPFL), Lausanne, Switzerland, in February 1998 as a senior lecturer. He was promoted to Assistant Professor in 2004, to Associate Professor in 2011 and is now a Full Professor since 2020. He also holds a 20% position at the Department of Radiology of the University of Lausanne (UNIL) and of the Lausanne University Hospital (CHUV) as Associate Professor ad personam. Dr Thiran's current scientific interests include
Computational medical imaging: acquisition, reconstruction and analysis of imaging data, with emphasis on regularized linear inverse problems (compressed sensing, convex optimization). Applications to medical imaging: diffusion MRI, ultrasound imaging, inverse planning in radiotherapy, etc.Computer vision & machine learning: image and video analysis, with application to facial expression recognition, eye tracking, lip reading, industrial inspection, medical image analysis, etc.
Hilal Lashuel2012-2013 Visiting Professor, Standford University. Stanford School of Medicine
2011- Associate Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Chemical Biology of Neurodegeneration
2005-2011 Assistant Professor of Life Sciences-Brain Mind Institute-EPFL
Dir. Laboratory of Molecular Neurobiology and Neuroproteomics
2005-2008 Director- EPFL Proteomic Core Facility
2002-2004 Instructor of Neurology- Harvard Medical School and Brigham and Women's
Hospital
2001-2002 Sabbatical Fellow- Laboratory for Drug Discovery in Neurodegeneration
Harvard Medical School,
2001-2002 Post-doctoral Fellow- Center for Neurologic Diseases
Harvard Medical School and Brigham and Women's Hospital
Advisor- Prof. Peter T. Lansbury
2000-2001 Research Scientist, The Picower Institute for Medical Research, Great Neck
New York
1994-2000 PhD Student; Texas A&M University and the Scripps Research Institute
Advisor- Prof. Jeffery W. Kelly
1990-1994 B.S. City University of New York, Brooklyn College
Dr. Hilal A. Lashuel received his B.Sc. degree in chemistry from the City University of New York in 1994 and completed his doctoral studies at Texas A&M University and the Scripps Research Institute in 2000. After obtaining his doctoral degree, he became a research fellow at the Picower Institute for Medical Research in Long Island New York. In 2001, he moved to Harvard Medical School and the Brigham and Women's Hospital as a research fellow in the Center for Neurologic Diseases and was later promoted to an instructor in neurology at Harvard Medical School. During his tenure (2001-2004) at Harvard Medical School his work focused on understanding the mechanisms of protein misfolding and fibrillogenesis and the role of these processes in the pathogenesis of Parkinson's and Alzheimer's disease. In 2005 Dr. Lashuel moved Switzerland to join the Brain Mind Institute at the Swiss Federal Institute of Technology Lausanne as a tenure-track assistant professor in neurosciences. Currently, Dr. Lashuel is an associate professor of life sciences and the director of the laboratory of molecular and chemical biology of neurodegeneration. (http://lashuel-lab.epfl.ch/).
Research efforts in the Lashuels laboratory focus on understanding the molecular mechanisms of neurodegeneration and developing novel strategies to diagnose and treat neurodegenerative diseases such as Alzheimers and Parkinsons disease. Research in the Lashuel lab is funded by several international funding agencies and foundations, including the Swiss National Science Foundation, European FP7 program (Marie Curie and ERC grants), Human Science Frontiers, Strauss Foundation, Cure the Huntingtons disease foundation and Michael J Fox foundation and is supported by collaborations with pharmaceutical and biotech companies (http://lashuel-lab.epfl.ch/page-50538-en.html), Nestle, Merck-Serono, AC Immune and Johnson and Johnson.
Dr. Lashuels research has resulted in the characterization of novel quaternary structure intermediates on the amyloid pathway, identification of potential therapeutic targets, and new hypotheses concerning the mechanisms of pathogenesis in Alzheimers disease, Parkinsons disease and related disorders. Dr. Lashuel scientific contribution to this field includes i) more than100 publications in major peer reviewed journals including Nature journals, Cell, PNAS, JBC, J. Neuroscience JACS, and Angewandtie Chemie; ii) three patents on novel strategies for preventing protein aggregation and treating autoimmune and inflammatory diseases; iii) more than 150 invited lectures since 2002 and more than 5500 citations (7800 citation-Google Scholar) since 1996. Dr. Lashuel has received several pre-doctoral and post-doctoral awards and fellowships and was the recipient of two prestigious awards given to young investigators; Human Science Frontiers young investigator research award and the European Research Council (ERC) starting independent researcher grant and the ERC proof of concept award (2013) These awards provide more than $2.5 Million to Dr. Lashuel to translate some of his ideas and projects into novel strategies for diagnosing and treating neurodegenerative diseases such as Alzheimers and Parkinsons disease. Dr. Lashuel has chaired and co-organized several international conferences and serves as an academic editor for PLoS ONE, an associate editor for frontiers of molecular neuroscience, member of the Editorial advisory board of ChemBioChem and ad hoc reviewer for several international scientific journals and funding agencies. Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Anthony Christopher DavisonAnthony Davison has published on a wide range of topics in statistical theory and methods, and on environmental, biological and financial applications. His main research interests are statistics of extremes, likelihood asymptotics, bootstrap and other resampling methods, and statistical modelling, with a particular focus on the first currently. Statistics of extremes concerns rare events such as storms, high winds and tides, extreme pollution episodes, sporting records, and the like. The subject has a long history, but under the impact of engineering and environmental problems has been an area of intense development in the past 20 years. Davison''s PhD work was in this area, in a project joint between the Departments of Mathematics and Mechanical Engineering at Imperial College, with the aim of modelling potential high exposures to radioactivity due to releases from nuclear installations. The key tools developed, joint with Richard Smith, were regression models for exceedances over high thresholds, which generalized earlier work by hydrologists, and formed the basis of some important later developments. This has led to an ongoing interest in extremes, and in particular their application to environmental and financial data. A major current interest is the development of suitable methods for modelling rare spatio-temporal events, particularly but not only in the context of climate change. Likelihood asymptotics too have undergone very substantial development since 1980. Key tools here have been saddlepoint and related approximations, which can give remarkably accurate approximate distribution and density functions even for very small sample sizes. These approximations can be used for wide classes of parametric models, but also for certain bootstrap and resampling problems. The literature on these methods can seem arcane, but they are potentially widely applicable, and Davison wrote a book joint with Nancy Reid and Alessandra Brazzale intended to promote their use in applications. Bootstrap methods are now used in many areas of application, where they can provide a researcher with accurate inferences tailor-made to the data available, rather than relying on large-sample or other approximations of doubtful validity. The key idea is to replace analytical calculations of biases, variances, confidence and prediction intervals, and other measures of uncertainty with computer simulation from a suitable statistical model. In a nonparametric situation this model consists of the data themselves, and the simulation simply involves resampling from the existing data, while in a parametric case it involves simulation from a suitable parametric model. There is a wide range of possibilities between these extremes, and the book by Davison and Hinkley explores these for many data examples, with the aim of showing how and when resampling methods succeed and why they can fail. He was Editor of Biometrika (2008-2017), Joint Editor of Journal of the Royal Statistical Society, series B (2000-2003), editor of the IMS Lecture Notes Monograph Series (2007), Associate Editor of Biometrika (1987-1999), and Associate Editor of the Brazilian Journal of Probability and Statistics (1987 2006). Currently he on the editorial board of Annual Reviews of Statistics and its Applications. He has served on committees of Royal Statistical Society and of the Institute of Mathematical Statistics. He is an elected Fellow of the American Statistical Assocation and of the Institute of Mathematical Statistics, an elected member of the International Statistical Institute, and a Chartered Statistician. In 2009 he was awarded a laurea honoris causa in Statistical Science by the University of Padova, in 2011 he held a Francqui Chair at Hasselt University, and in 2012 he was Mitchell Lecturer at the University of Glasgow. In 2015 he received the Guy Medal in Silver of the Royal Statistical Society and in 2018 was a Medallion Lecturer of the Institute of Mathematical Statistics.
Valerio ZerbiDr. Valerio Zerbi is a pioneer of preclinical magnetic resonance functional neuroimaging. At his lab at EPFL, Valerio and his team use functional MRI recordings in rodents in combination with neural modulation and computational approaches to study the mechanisms that link cellular activity to large-scale network (dys)function. His long-term ambition is to advance the development of personalised strategies based on imaging and artificial intelligence, for the diagnosis and prognosis of developmental brain disorders. Valerio is the recipient of the ETH Postdoctoral (2014), the Swiss National Science Foundation AMBIZIONE
(2017) and ECCELLENZA (2021) fellowships.
